Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmer's test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as 'responders' when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.
INTRODUCTION
Ocular GVHD (oGVHD) rarely arises in acute GVHD but occurs in 40-60% of patients with chronic GVHD (cGVHD) after allo-SCT; 1 it occurs in 60-90% of patients affected with extensive cGVHD, more frequently after a related SCT, and when the skin or mouth are involved. [2] [3] [4] oGVHD has protean clinical manifestations, affecting multiple parts of the eye, including conjunctiva, lacrimal gland, cornea, the lid and the vitreous. 5 It frequently develops as dry eye syndrome (DES) with a prevalence ranging from 10 to 62%, 3 presenting mainly with keratoconjunctivitis sicca, conjunctival inflammation and chronic blepharitis often associated with infectious conjunctivitis. DES complications may become irreversible and lead to permanent visual loss. 3 DES is classified by the NIH consensus criteria with a scale ranging from 0 (no dry eye symptoms) to 3 (pain and visual loss significantly affecting daily living). 6 Pathophysiology is complex, and includes fibroblastic and T-lymphocytic infiltrates in the lacrimal gland with consequent deficiency in lacrimal production owing to fibrosis. 7 DES clinical characteristics resemble those found in some autoimmune diseases (for example, Sjö gren's syndrome).
Despite many advances in understanding the pathophysiology, there is a paucity of good-quality studies on therapeutic options for this condition. 5 oGVHD responds poorly to both systemic and local immunosuppressive therapy, which, at the same time, increase the risk of infectious complications. 5 Furthermore, in cases of response to systemic immunosuppressive therapy, oGVHD frequently worsens when it is tapered. 2 The local therapies most commonly used to reduce ocular inflammation and corneal lesions (corticosteroids, CsA, tacrolimus and others) in association with artificial tears, demonstrated poor tolerance and unsatisfactory response. 3, 5, 9 For instance, a recent meta-analysis estimated that topical lubricants provide an overall improvement that is no greater than 25% from baseline, while topical CsA achieved improvement in only 10/16 (62%) patients. 10, 11 Recently, borrowing from the experience of patients with severe DES in Sjö gren's disease, 12, 13 treatment with autologous serum eye drops has been proposed to treat refractory keratoconjuntivitis sicca in GVHD patients with good results, demonstrating that serum is safe and effective in the majority of patients after 4 weeks of treatment. [14] [15] [16] Autologous serum is rich in several growth factors, vitamins and fibronectin, all active elements involved in maintaining corneal and conjunctival integrity. 12, 16, 17 In the past decade, autologous plasma rich in growth factors (PRGs) has been successfully used in tissue repairing. 18, 19 Recently, our group demonstrated that PDGFs have a pivotal role in the maintenance of corneal integrity, interacting with the different corneal cellular components having a crucial role in the renewal of corneal epithelium and wound healing processes. 20 Also, we achieved good results in refractory oral mucositis associated with cGVHD using PRGs, extracted from platelet a-granuli by the freezing-thawing method. 21 Starting from this favorable experience, under the working hypothesis of an enhanced therapeutic effect of higher concentrations of PDGFs in plasma after platelet disruption, we undertook this study on refractory oGVHD using autologous plasma rich in PDGFs eye drops (PRGD), with the aim of determining the clinical efficacy and safety of this preparation. [20] [21] [22] 
PATIENTS AND METHODS

Setting and study design
This study was conducted from January 2009 to June 2011 at the teaching hospital of Pavia, Italy (B1200 beds, with a BMT unit that performs 40 allogeneic BM transplants/year since 1981, and a referral centre from other Italian regions). The study was approved by our Ethical Committee.
Patients gave their consent before inclusion. It is a single-arm, single-step, phase 2 clinical trial. Eligibility criteria were as follows:
(1) cGVHD with oGVHD showing DES (at least grade 2, according to the Dry Eye Severity Grading Scheme) 23, 24 roughly corresponding to the 1-3 scoring in the NIH classification of eye manifestations of cGVHD. Any other local therapy was stopped 48 h before starting PRGD treatment.
Preparation of autologous PRGD
Hemocytometric analysis was performed before each PRGD preparation. A volume of 40 mL of anticoagulated (ACD-A) peripheral blood was sampled from each patient and centrifuged at 900 r.p.m. for 10 min to obtain autologous platelet-rich plasma. The platelet-rich plasma was diluted with a sterile saline solution at a final concentration of 30% (v/v), then aliquoted in 1.5-mL sterile vials, freezed at À 80 1C for at least 60 min (thermal shock) and thawed at 4 1C, to induce platelet lysis and PDGF release. A sample for bacterial and fungal detection was collected at the time the product was prepared. All manipulations were performed under sterile conditions. The final product was then freezed again at -20 1C and stored in patients' own freezer for a maximum of 45 days.
PDGFs quantification
Among all PDGFs, we selected PDGF-AB, epidermal growth factor (EGF), vascular endothelial growth factor, insulin-like growth factor 1 and transforming growth factor-b, owing to their wide range of activity on cell proliferation, cell migration and angiogenesis. At the time of enrollment peripheral blood samples (3 mL) were collected from patients and stored at À 80 1C until analysis. The concentrations of PDGF-AB, EGF, vascular endothelial growth factor, insulin-like growth factor 1 and transforming growth factor-b1 in patients' plasma samples were evaluated using a quantitative ELISA method (Quantikine, R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
Treatment and ophthalmological assessments
To minimize the contamination risk, patients were instructed to thaw each vial separately, to store at 4 1C during use (maximum 24 h) and to instill PRGD by a sterile disposable pipette four times/day. Treatment continued during the entire follow-up (180 days). In the case of conjunctivitis, appropriate local therapy was started, and PRGD treatment was suspended and resumed after resolution; to check possible bacterial or fungal contamination of the stored PRGD vials, patients were instructed to bring back the vials for microbiological cultures.
To reduce variability in clinical assessments, patients were evaluated by the same ophthalmologist at the time of enrollment and after 30, 90 and 180 days of treatment. Dry eye symptoms were assessed by a patient selfadministered questionnaire derived from the Glaucoma Symptoms Scale using only symptoms related to conjunctival involvement and recently validated in Italian language by one of us (Table 1) . [25] [26] [27] The objective findings included best-corrected visual acuity for distance, Schirmer's test (without local anesthesia), assessment of tear film using the tear break up time test (expressed as mean value after three measurements), biomicroscopy of the anterior segment, and corneal fluorescein staining and conjunctival lissamine staining, both evaluated following the Oxford scheme. 28 Biomicroscopy was evaluated using a customized scale (grade 0 ¼ normal; grade 1 ¼ minimal epithelial defects; grade 2 ¼ epitheliolysis; grade 3 ¼ mild keratitis; grade 4 ¼ severe keratitis; and grade 5 ¼ ulcer).
Patients were defined as 'responders' when showing improvement for symptoms (defined as improving at least 5 points in total complaint score) and for at least one sign (defined as improving at least 1 point).
Statistical issues
The sample size was based on an expected 80% response rate at 30 days (vs a response rate of 50%, deemed not clinically relevant) to be detected with 90% power and a error 5%. 
RESULTS
Patients' characteristics
Characteristics of the patients enrolled in the study are shown in Table 2 . Briefly, 23 patients (15 males and 8 females), mean age 48.5 years (range 26-66), were enrolled. They underwent SCT for different diseases (10 AML, 6 multiple myeloma, 3 Hodgkin's disease, 1 myelodysplastic syndrome, 1 CLL, 1 CML and 1 ALL). In all, 7 patients (30.4%) received BM-SCT and 16 patients (69.6%) PB-SCT. A total of 16 SCTs were related and 7 were unrelated. All patients had extensive cGVHD, mainly affecting the skin (n ¼ 21, 91.3%) and mucosae (n ¼ 17, 73.9%) with ocular involvement (range 1-3 organs involved). Prior treatment of oGVHD included topical CYA in 2 (13.1%) patients, artificial eye drops and steroids in 18 (78.3%) and autologous serum in 7 (30.4%). Median platelet count in peripheral blood was 323 800/mL (interquartile range 138 000-746 000/mL). PDGFs quantification is reported in Table 3 .
Treatment and ophthalmological evaluation At enrollment, all patients showed at least a grade 2 DES (median 4, interquartile range 3-5, range 2-5). Three (13%) patients did not complete 6-month follow-up, one dropped out after 30 days and two after 90 days, all for purely logistic reasons. Optimal compliance to PRGD was observed in all patients. No bacterial or fungal contamination was detected in PRGD samples, and no contamination during storage emerged. Three conjunctivitis episodes were observed in three patients, with a maximum duration of 4 days; in all cases, microbiological cultures of the residual PRGD in the vials were negative.
Symptoms and signs of the ocular surface evaluated at baseline and after 30, 90 and 180 days are shown in Table 4 . After 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%), while pain only improved in 13 patients 
Patients were asked to answer the questions 'Have you experienced any of the following problems from the last follow-up? How many times?' and the symptoms were graded according to their severity using a scale ranging from 0 to 4. The total score is obtained by adding up individual scores, and ranges from 0 (no symptoms) to 20 (manifestation of all symptoms all of the time).
Autologous platelet lysate for ocular GVHD S Pezzotta et al (56.5%). Tear break up time improved in 20 patients (86.9%; Table 5 ) and fluorescein corneal staining in 16 (69.6%; Figure 1 ). Of the six non-responding patients, two did not show improvement in any of the symptoms and signs, and the remaining four had a limited improvement although not reaching the criteria for defining response.
In the course of steroid treatment, 9/23 (39.1%) patients developed cataracts, 2 of which also needed surgical correction.
Treatment outcome was not significantly related at univariate analysis to stem cell source (BM or PBSC), type of donor, type and number of organs involved other than eyes, time from cGVHD to therapy with PRGD (range 2-104 months), time from transplant to cGVHD (range 4-92 months) and PDGFs concentration in plasma.
DISCUSSION
Our study demonstrates the efficacy of autologous PRGD in patients unresponsive to prior treatments, with good results on all GVHD-related ocular outcomes. At 30 days, around 80% of patients responded, despite the fact that many had severe DES. Of note, our definition of response was very conservative (improvement in all symptoms and at least one sign). Response was also maintained at 6 months.
All GVHD-related ocular symptoms improved in most patients, particularly photophobia, which is one of those that impact heavily on patients' quality of life and daily activities.
Tear break up time improved in all responders and was associated with a variable improvement of all other signs; in fact, Autologous platelet lysate for ocular GVHD S Pezzotta et al Table 4 . Autologous platelet lysate for ocular GVHD S Pezzotta et al the improvement of the anterior segment surface is accompanied by a reduction of fluorescein staining (expression of corneal epithelium loss) and conjunctival lissamine staining (that assesses dead conjunctival cells). The reduced corneal damage determines a better and prolonged tear film stability. Interestingly, best-corrected visual acuity did not significantly improve; in fact, decline in visual acuity is probably related to other causes (for example, conditioning regimen and steroids) that determine cataract onset. Also, Schirmer's test did not change significantly, because PRGD therapy cannot reduce the damage caused by fibroblastic and lymphocytic infiltrates in the lacrimal glands. However, Schirmer's test should be assessed at the time of treatment to correctly determine the disease stage.
Despite the fact that most responders did not obtain complete normalization of symptoms and signs, the improvement obtained was sufficiently marked as to provide significant amelioration of patients' quality of life and return to daily life activities, in particular reading, driving and computer usage.
We suggest that ophthalmological evaluation becomes a part of the standard monitoring of cGVHD patients, to promptly identify patients with oGVHD at an early stage; this should prompt timely treatment of ocular lesions, to avoid the irreversible complications that deeply compromise visual acuity and quality of life, and for which no effective treatment exists. 2, 3, 5, 8 In particular, in our opinion, if DES grade is p1, patients should be treated with preservative-free artificial tears, if DES is 41, patients can undergo PRGD therapy, to be maintained long term if responders.
However, we also advise that PRGD should not be used for extensive ulcers where neovascularization (natural repairing mechanism of corneal stroma) has already occurred, because PDGFs might further increase the formation of new vessels and subsequent corneal opacity, speeding up visual loss. 29, 30 PDGF-AB, EGF, vascular endothelial growth factor, insulin-like growth factor 1 and transforming growth factor-b1 are involved in the network of proliferation, differentiation, migration and apoptosis of corneal cells contributing to epithelial renewal. [31] [32] [33] There is in vitro evidence that PRG is richer in PDGF-AB, EGF and transforming growth factor-b1 than serum and better stimulates growth of corneal epithelial cells. 22 This encouraged the use of PRGs for treating DES, corneal lesions, neurotrophic keratitis and persistent corneal epithelial defects with promising results. 22, [34] [35] [36] [37] In fact, PRG has recently been shown to be effective in a variety of autoimmune diseases involving the eye and causing DES. 38 The prompt corneal re-epithelization triggered by the cooperation of PDGFs (such as EGF, PDGFA-B, promoting in particular cell proliferation) and the inhibitors of inflammation (for example, IL-1 receptor antagonist and inhibitors of metalloproteinases) 18, 22 may explain the excellent results we obtained as early as at 30 days of treatment also in this difficult set of patients. Response was also observed in patients with very severe corneal damage and in those with longer history of oGVHD. Interestingly, seven of our patients had not previously responded to autologous serum but responded to PRGD, this might be explained by the higher concentration of PDGFs in PRGD than in serum. 22 We did not find an association between PDGFs concentration or number of platelets in peripheral blood and response. The high interpatient variability in individual PDGFs may explain this finding, as our study was insufficiently powered to detect this effect. 39 As all patients had a relatively high and homogeneous number of platelets in peripheral blood, we can postulate that PDGFs balance in PRGD was high enough to induce corneal repair in all patients, even if the minimal concentration of PDGFs sufficient to trigger the healing process is not known.
We prepared PRGD using autologous platelet-rich plasma after freezing thawing at a final dilution of 30% 20 rather than with a chemical mechanism as used by others, 38 to avoid the risk of sensitization and consequent poor tolerability. 5 Based on the high concentration of PDGFs in PRGD, we also decided to reduce the frequency of instillation to four times a day to ensure better patient compliance. For comparison, serum has been usually administered 10 times a day. 15 The use of autologous PRGD avoided the risk of infections related to the use of homologous blood. Importantly, we had to consider the heavy immunosuppressive status of our patients and the concern for contamination and infection possibly associated with use of a single vial for several times. 5 We thus prepared small aliquots of PRGD to be used for a maximum of 24 h at 4 1C and instructed patients to an accurate manipulation. In fact we did not observe any conjunctivitis related to PRGD contamination. To our knowledge, this is the first study using platelet lysate in the field of oGVHD; its strengths are that the patient population was represented by patients unresponsive to other treatments, and therefore it might prove even more useful as a first-line treatment; second, we used a new methodology for preparation and storage, to overcome the drawbacks of previous therapeutic attempts with serum; finally, a single ophthalmologist performed all clinical assessments, therefore it is unlikely that changes in clinical parameters are because of different interpretations.
However, a number of important limitations need highlighting. First, the limited sample does not allow more in-depth analyses on factors favoring response. In fact, despite its impact on quality of life, oGVHD is often clinically considered a 'second-rate' manifestation of cGVHD, and few patients are referred to the ophthalmologist, often late in the course of disease.
Furthermore, the clinician was not blind to the treatment. Also, there was no control group because the condition of the ocular surface can deteriorate rapidly in patients with cGVHD, and it may be difficult to select control subjects to be treated with conventional artificial eye drops, as acknowledged by others. 15 In addition, follow-up was somewhat limited and we cannot reach conclusions on long-term efficacy; in this respect, it is also not possible to compare long-term efficacy of autologous PRGD and serum due to the limited data available.
CONCLUSIONS
In our experience PRGD proved, at least in the short term, to be effective, well tolerated, safe and of relatively low cost.
